FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Nutrition & Health News

Food for the heart (Part 2): Consumer trends and innovations

19 Oct 2017 --- Food for heart health is a key trend in nutrition NPD, with many companies exploring ways in which to protect consumers against cardiovascular issues. Today, in the second part of a special report, NutritionInsight examines which consumer trends are driving innovation in the world of heart health products and what these innovations are.

Nutrition & Health News

Food for the heart (Part 1): Opportunities, challenges and delivery forms

16 Oct 2017 --- Heart health is literally a matter of life and death – according to the US Centers for Disease Control and Prevention (CDC), about 610,000 people die of heart disease in the US every year. This means that it accounts for 1 in every 4 deaths. Indeed, heart disease is the leading cause of death for both men and women, so potential nutritional solutions are at the forefront of companies’ thinking.

Nutrition & Health News

Synbiotics: The best of both worlds (Part 2) – Innovations and NPD opportunities

06 Oct 2017 --- Synbiotics – dietary supplements or functional food ingredients that contain both prebiotics and probiotics – are seeing a lot of innovations and new products take hold within their specialized space. Today, in the second part of a special report, NutritionInsight looks at these changes with some insights from companies that are producing synbiotics.

Regulatory News

ID Nutra’s satiety product gets EFSA novel food nod

28 Sep 2017 --- The thirst and hunger suppressing specimen H. parviflora, marketed by ID Nutra as SatiPlus, has been approved as a novel food by the European Food Safety Authority (EFSA). The product’s potential benefits include a host of advantages related to weight loss and metabolism.

Nutrition & Health News

NP Nutra introduces Triple-T Verification Program

26 Sep 2017 --- Nature’s Power Nutraceuticals Corp (NP Nutra), a wholesale supplier of premium nutraceutical ingredients is to launch its Triple-T Verification Program at Supply Side West, which aims to guarantee the quality and traceability of its supply chain.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html